Admin

After being suppressed by Eli Lilly for two years, how Novo Nordisk strikes back: "Bowing to Trump" to obtain tariff exemptions, exchanging profits for speed to race ahead with new drugs.

After being suppressed by Eli Lilly for two years, how Novo Nordisk strikes back: "Bowing to Trump" to obtain tariff exemptions, exchanging profits for speed to race ahead with new drugs.

After experiencing the darkest moment of its stock halving and losing the throne of “weight-loss drug king,” Danish pharmaceutical giant Novo Nordisk is trying to regain market dominance through a bold political gamble and accelerated product strategy. Faced with fierce competition from Eli Lilly, the new Novo Nordisk management has